ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chinese expert consensus on the diagnosis and treatment of POEMS syndrome (2025)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- POEMS syndrome complicated by portal hypertension resembling decompensated cirrhosis: a case report and diagnostic insights.Frontiers in medicine · 2025Article
- Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POEMS syndrome is a rare plasma cell disorder characterized by diverse clinical manifestations, making patients susceptible to missed diagnosis and misdiagnosis, which can delay treatment and adversely affect prognosis. There is no gold standard for diagnosing POEMS syndrome; the diagnosis primarily relies on a comprehensive assessment of clinical and laboratory findings. The application of autologous hematopoietic stem cell transplantation and novel agents has led to significant improvements in both the treatment and prognosis of POEMS syndrome. This consensus addresses the diagnostic challenges associated with POEMS syndrome and provides treatment recommendations for both transplant-eligible and transplant-ineligible patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.